Rhizome AI Launches: Know What The FDA Thinks

Rhizome AI recently launched!

^‍

^{"Instantly answer regulatory questions with up to 1,000 documents from public health authority databases without hallucinations."}

^‍

^{TL;DR What has the FDA’s feedback been on real world evidence in review comments? Rhizome AI helps life science companies know what the FDA thinks.}

‍

^{Regulatory affairs teams ask a question and get an answer backed by terabytes of regulatory & clinical databases from the US, EU, etc.}

‍

^{Unlike ChatGPT, Rhizome reads up to 1,000 documents per question, accompanies each statement with a citation, and doesn’t hallucinate.}

‍

Founded by Chetan Mishra

Hi everyone, meet Chetan, the founder of Rhizome AI.

‍

Ask: If you know any biotech or medtech leaders (esp. if they’re regulatory affairs or R&D), Chetan would appreciate an intro!

Ultimately Chetan wants all reg affairs teams to be as informed as the most regulatory man in the world.

‍

🤝 Who The Founder Is

A bit about Chetan's background. He joined EvolutionaryScale as their first product engineer, launching an AI inference platform to help scientists design proteins. He joined Instabase as #16 helping banks with document & imaging processing, closing $7m as the technical lead. When looking to start his own company, Chetan realized there are many AI startups focused on drug discovery, but a lot less attention bringing those products to market.

‍

😖 The Problem: Knowing What The FDA Thinks

The FDA is the customer of every function in life sciences. It doesn’t matter whether you are regulatory affairs, R&D, quality, manufacturing, commercial, etc.

At the same time, it’s difficult to understand their thinking. Guidance documents are high level and vague. The only alternative is doing (or paying a consultant to do) manual, painful research on past decisions they’ve made and understand why. Other regulators around the globe are no easier.

ChatGPT / Claude / etc. have only made it worse:

• They trust their knowledge and only look up what they feel the need to. This means low-latency, but high-hallucination research.
• Even when they retrieve sources, at most, it’s a few dozen. It’s also liable to include lots of internet junk mixed in with the authoritative government databases the industry trusts.
• They don’t make it easy to check citations. They cite a 1200 page PDF and you don’t really know where to dig inside it.

‍

✨ The Solution: Hallucination-Free, Deep Research For Life Sciences

Rhizome solves this problem by providing hallucination-free and thorough deep research for the life sciences. There’s a few key things their customers like:

• Rhizome didn’t have a single hallucination reported in 2025.
• Every statement comes with a citation.
• Rhizome reads up to 1,000 documents per question in a few minutes before writing an answer. They’re continuously extending this limit.

Here’s a quick peek at the product:

‍

Rhizome customers love it. A few testimonials:

• “Last time we did this research, we spent weeks. Rhizome found the answer immediately.” - a VP of reg affairs at a clinical-stage biotech.
• “Chetan idk what kind of magic you all did here, it’s so good.” - a VP of reg affairs at a biotech with multiple products on the market.
• “I would cry if I lost access to Rhizome.” - an RA manager at a drug delivery device company.
• “10 minutes of work can accomplish what would have taken weeks.”- a device engineer at a pharma company.

‍

Learn More

^‍

^{🌐 Visit rhizomeai.com to learn more.}

^‍

^{🙏 The Ask: Connections with regulatory affairs, quality, or R&D leaders in life sciences.}

^‍

^{🤝 Do you know any regulatory affairs, quality, or R&D leaders in life sciences? It would be awesome to chat with them!}

‍

^{📣 Share this post with your friends / family in life sciences!}

‍

^{👣 Follow Rhizome AI on LinkedIn.}

‍